Search
SOLACI Congress
HomePharmacologyAntithrombotic Anticoagulants

Antithrombotic Anticoagulants

View Category

Antithrombotic Anticoagulants

ESC 2018 | MARINER: Rivaroxaban as Thromboprophylaxis after Hospitalization

For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after...
solaci -
Learn More
Antithrombotic Anticoagulants

NSAIDs and Risk of Bleeding in Patients with Atrial Fibrillation

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is very frequent and many of these medications are sold...
solaci -
Learn More
Acute coronary syndromes

NCDR ACTION Registry: Anticoagulated Patients with No Higher Risk of Bleeding in Emergency Procedures

Patients with a history of atrial fibrillation treated with warfarin or any of the new direct oral anticoagulants undergoing...
solaci -
Learn More
Antithrombotic Anticoagulants

The End of Aspirin for Anticoagulated Patients Undergoing PCI

The discussion about the best anti-thrombotic strategy for patients with atrial fibrillation undergoing PCI seemed never-ending until the RE-DUAL...
solaci -
Learn More
Antithrombotic Anticoagulants

COMPASS: A New Place for Rivaroxaban in Chronic Ischemic Heart Disease

Combining low doses of rivaroxaban and aspirin seems to be the best strategy for patients with stable...
solaci -
Learn More
Acute coronary syndromes

VALIDATE-SWEDEHEART: bivalirudin seems to be losing ground

Another important work that does not see the benefits of bivalirudin over heparin as monotherapy as regards both...
solaci -
Learn More
Antithrombotic Anticoagulants

RE-DUAL PCI: Anti-Thrombotic Management in Patients with Atrial Fibrillation and PCI

RE-DUAL PCI outcomes have been published by the  New England Journal of Medicine along with their presentation at...
solaci -
Learn More
Acute coronary syndromes

Transradial access shows no benefit of bivalirudin

The aim of this study was to compare bivalirudin against heparin in patients with ST elevation acute...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy